Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nonprofit Pharma Targets Making Naloxone Available OTC, Trimming Price

Executive Summary

Nonprofit Harm Reduction Therapeutics targets an OTC switch of naloxone, an opioid antagonist used to reverse an opioid overdose. It aims to make the product available at low cost in 110,000 retail locations nationwide.


Related Content

Gottlieb An Anchor For OTC Drug Industry On Stormy Congressional Seas
Medtech Tools To Help Address Opioid Crisis Face Reimbursement Challenges
FDA Looks At OTC Loperamide Packaging To Curb Opioid-Related Abuse
Opioid, NME, And Generic Drugs Changes Plotted In US FDA's 2018 Policy Roadmap
Declaring Opioid Emergency, Trump Touts FDA Actions, NIH-Industry Partnerships
FDA's OTC Naloxone Study Is A Starting Point For Other Switches, Not A Roadmap
Amphastar's Naloxone Nasal Spray Delayed; User Human Factors Study Among FDA Concerns
CHPA Optimistic Voluntary Drug Takeback Efforts Will Stall Spread Of Mandates


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts